Trajan Scientific and Medical (Trajan) is pleased to be part of launching the ARC Centre for Personalised Therapeutics Technologies (ARC CPTT) today in Melbourne, Australia. The center aims to provide a world-leading commercial advantage in developing therapeutic treatments.
Headquartered at the Department of Pharmacology and Therapeutics at the University of Melbourne, the center brings together the University of Melbourne, Monash University, University of Western Australia, and 17 partner organizations in government and industry.
ARC CPTT is training a new generation of enterprising biomedical researchers. It aims to transform the medical technologies and pharmaceutical (MTP) industry’s access to emergent technologies that enable accelerated translation of discoveries into benefits for end users.
Mr Stephen Tomisich, CEO, chair and founder of Trajan Scientific and Medical, said that ARC CPTT’s research in mechanistic, diagnostic, and therapeutic precision medicine complements Trajan’s strategic direction to improve human wellbeing through analytical measurements - which play an increasingly important role in producing meaningful and reliable data to inform healthcare.
“We strongly believe in our collaboration model to drive innovation and proliferation of technologies; so investing in ARC CPTT is another embodiment of our approach.” said Mr Tomisich.
“Being an Australian-based manufacturer and exporter on the global stage, we see our role as not only be an active industry participant supporting early career researchers; but also a device manufacturing and commercialization partner with other participants,” he said.
Trajan is also the sole industry founder another ARC Industrial Transformation Training Centre, ASTech, ARC Training Centre for Portable Analytical Separation Technologies. Since its establishment in 2013 with academic founder University of Tasmania; ASTech has expanded to include the University of South Australia in 2016, and La Trobe University in 2017, and continues to provide industry experience within Trajan and its partners.
Trajan has seen the benefit of student participation bringing fresh perspective and talent, while industry engagement brings expertise, guidance and visibility on emerging trends in the scientific and clinical community.
“We have many R&D and commercialization programs underway, but an exciting example which began with ASTech, is the commercial release of first-generation hemaPEN® microsampling technology this year.” he said.
hemaPEN provides a minimally invasive and convenient sampling procedure for collecting four identical dried blood spot (DBS) based samples.* The proposed concept of the hemaPEN platform technology was developed in 2015 by ASTech, with the commercialization pathway realized by Trajan.
“With ARC CPTT, we hope to promote the same collaborative and commercial success in the medtech and pharmaceutical (MTP) sector that we have been nurturing in analytical science.” he said.
Photo (L-R): Prof Robyn Owens, Deputy Vice-Chancellor (Research), University of Western Australia; Dr Dan Grant, CEO, MTPConnect; Assoc Prof Kevin Pfleger, Deputy Director, ARC CPTT, and Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research and the Centre for Medical Research, The University of Western Australia; Dr Andrew Gooley, Chief Scientific Officer and Director, Trajan Scientific and Medical; Prof Duncan Maskell, Vice-Chancellor, University of Melbourne; Prof Ian Smith, Vice-Provost (Research and Research Infrastructure), Monash University; Prof Sue Thomas, CEO, Australian Research Council; Prof Alastair Stewart, Centre Director, ARC CPPT, and Chair, Therapeutic Technologies Research Initiative, and Co-Director, Lung Health Research Centre, University of Melbourne.
Photo: ARC CPTT launch event, University of Melbourne, Australia.
ARC CPTT partners
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1244 403 100
*The hemaPEN is under development and the prototype device is supplied for research or investigational purposes only. This device is not for therapeutic or diagnostic use. For more information, visit www.hemapen.com.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.